Bionano Genomics Gestione
Criteri Gestione verificati 3/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Al Luderer
Amministratore delegato
US$95.7k
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | no data |
| Proprietà del CEO | n/a |
| Durata media del management | 5yrs |
| Durata media del Consiglio di amministrazione | 7.4yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • May 03
BNGO: Clinical Evidence For Genome Mapping Will Support Long-Term Upside
Analysts have maintained their $6.00 price target for Bionano Genomics, noting only minor adjustments to assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially change their overall view on the stock. What's in the News Bionano Genomics reported that its auditor, BDO LLP, issued an unqualified opinion in the 2025 Form 10-K while expressing doubt about the company’s ability to continue as a going concern, highlighting funding and liquidity risk that equity holders should monitor closely (10-K filing).Aggiornamento della narrazione • Apr 19
BNGO: Gene Editing QC And Hematology Evidence Will Drive Long-Term Upside
Analysts have reduced their price targets for Bionano Genomics, lowering updated fair value estimates to $6.00 from $8.00, alongside slightly lower revenue growth and profit margin assumptions and a marginally reduced future P/E outlook. What's in the News Bionano Genomics published a multicenter study in the American Journal of Hematology showing that optical genome mapping, or OGM, identified pathogenic or likely pathogenic abnormalities in multiple myeloma samples, including cases where traditional methods such as karyotyping, FISH, and NGS had limited success or returned no result (American Journal of Hematology).
Aggiornamento della narrazione • Apr 05
BNGO: Future Gene Editing Quality Control Breakthroughs Will Drive Upside Potential
Analysts have cut their price target on Bionano Genomics roughly in half, to around $4.00 from about $8.00, pointing to a higher discount rate, slightly softer revenue growth expectations near 26%, a modestly better profit margin near 16%, and a higher future P/E multiple closer to 8x as key drivers of the reset. What's in the News A multicenter study in the American Journal of Hematology reported that Bionano's optical genome mapping, or OGM, was concordant with traditional methods in multiple myeloma and identified pathogenic or likely pathogenic abnormalities in a large cohort of 211 samples, including cases where standard tests such as karyotyping and FISH did not yield results (American Journal of Hematology).
Aggiornamento della narrazione • Mar 22
BNGO: Gene Editing Safety Data Will Support Future Upside Potential
Analysts have adjusted their price target for Bionano Genomics slightly, reflecting updated assumptions around discount rate, profit margin, revenue growth and future P/E. Together, these factors point to a modest recalibration of their valuation outlook in dollar terms.Aggiornamento della narrazione • Mar 07
BNGO: Gene Editing Safety Insights Will Support Long-Term Upside Potential
Analysts have lowered their price target on Bionano Genomics by $2.00 to $5.50, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. These changes collectively point to a more conservative outlook for the shares.Aggiornamento della narrazione • Feb 20
BNGO: Gene Editing Study And Mapping Sensitivity Will Support Future Upside
Analysts have raised their price target for Bionano Genomics to $12.59 from $12.37, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that reflect a recalibrated risk and earnings profile. What's in the News Bionano Genomics highlighted a peer-reviewed study in Molecular Therapy: Methods & Clinical Development that used optical genome mapping, or OGM, to assess genomic alterations from multiple gene editing approaches, including transposons, lentiviral transduction, and CRISPR-Cas9 locus insertion (Key Developments).Aggiornamento della narrazione • Feb 06
BNGO: Gene Editing QC Study Will Support Long-Term Upside
Analysts have trimmed their price targets for Bionano Genomics, citing slightly higher assumed discount rates and modest tweaks to long term revenue growth, profit margin and future P/E assumptions that leave their fair value estimate broadly unchanged at around $8.00. What's in the News Bionano Genomics highlighted a peer-reviewed study in Molecular Therapy: Methods & Clinical Development that used its optical genome mapping (OGM) technology to detect genomic alterations introduced by transposons, lentiviral transduction and CRISPR-Cas9 locus insertion in human iPSC lines, supporting OGM as a potential tool for genome integrity QC in gene editing workflows (Key Developments).Articolo di analisi • Jan 30
Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Revenues
With a price-to-sales (or "P/S") ratio of 0.5x Bionano Genomics, Inc. ( NASDAQ:BNGO ) may be sending very bullish...Aggiornamento della narrazione • Jan 23
BNGO: Clinical Study And Genome Mapping Progress Will Support Future Upside
Analysts have adjusted their price target on Bionano Genomics slightly, reflecting modest tweaks to assumptions on discount rate, profit margin, and future P/E. These changes keep their fair value estimate broadly unchanged at about $7.50 per share.Aggiornamento della narrazione • Jan 09
BNGO: Leukemia Study And 2025 Revenue Outlook Will Support Long-Term Upside
Analysts have slightly adjusted their price target for Bionano Genomics, citing modest tweaks in assumptions around discount rate, revenue growth, profit margin, and future P/E as the drivers of this update. What's in the News Bionano Genomics issued earnings guidance for the fourth quarter of 2025, with revenue projected in a range of US$7.5 million to US$7.9 million.Aggiornamento della narrazione • Dec 23
BNGO: Study-Driven Revenue Outlook Will Support Stronger Long-Term Upside Potential
Analysts have lowered their fair value estimate for Bionano Genomics from 11.00 dollars to 8.00 dollars. This reflects a higher perceived risk and cost of capital, despite slightly stronger expectations for revenue growth, profitability, and future valuation multiples.Aggiornamento della narrazione • Dec 09
BNGO: Clinical Study Momentum Will Drive Stronger Demand And Upside Through 2025
Analysts have modestly reiterated their outlook on Bionano Genomics, keeping the price target effectively unchanged as incremental tweaks to the discount rate, revenue growth, and margin assumptions suggest a steady, but not markedly altered, risk reward profile. What's in the News Bionano Genomics issued new revenue guidance for fourth quarter 2025, targeting $7.5 million to $7.9 million, while reiterating full year 2025 revenue expectations of $26.0 million to $30.0 million (company guidance filing).Aggiornamento della narrazione • Nov 25
BNGO: Clinical Study Results Will Drive Increased Demand Through 2025
Analysts have lowered their price target for Bionano Genomics from $9.50 to $7.50 per share, citing updated forecasts for valuation and growth. What's in the News Bionano Genomics initiated earnings guidance for the fourth quarter of 2025, projecting revenue between $7.5 million and $7.9 million, and reiterated full-year 2025 revenue guidance of $26.0 million to $30.0 million (company guidance).Articolo di analisi • Sep 14
A Piece Of The Puzzle Missing From Bionano Genomics, Inc.'s (NASDAQ:BNGO) 28% Share Price Climb
Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders would be excited to see that the share price has had a great month...Aggiornamento della narrazione • Aug 15
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
With both the consensus price target and future P/E holding steady, no notable valuation shift is apparent for Bionano Genomics, keeping fair value unchanged at $9.00. What's in the News Peer-reviewed study demonstrated Bionano's optical genome mapping (OGM) detects novel oncogenic structural variants in infant/toddler T-cell acute lymphoblastic leukemia missed by conventional cytogenetics, identifying distinct prognostic subgroups.Articolo di analisi • Jul 30
Investors Continue Waiting On Sidelines For Bionano Genomics, Inc. (NASDAQ:BNGO)
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong buy...
Nuova narrazione • Apr 16
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
Enhancements in customer utilization and lab efficiency are projected to boost consumable sales and revenue growth.Articolo di analisi • Apr 05
Revenues Working Against Bionano Genomics, Inc.'s (NASDAQ:BNGO) Share Price Following 26% Dive
To the annoyance of some shareholders, Bionano Genomics, Inc. ( NASDAQ:BNGO ) shares are down a considerable 26% in the...Articolo di analisi • Feb 11
Slammed 62% Bionano Genomics, Inc. (NASDAQ:BNGO) Screens Well Here But There Might Be A Catch
Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders that were waiting for something to happen have been dealt a blow...Articolo di analisi • Dec 17
Bionano Genomics, Inc. (NASDAQ:BNGO) Might Not Be As Mispriced As It Looks
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy...Articolo di analisi • Aug 29
Many Still Looking Away From Bionano Genomics, Inc. (NASDAQ:BNGO)
Bionano Genomics, Inc.'s ( NASDAQ:BNGO ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy...AMMINISTRATORE DELEGATO
Al Luderer (76 yo)
no data
Mandato
US$95,720
Compensazione
Dr. Albert A. Luderer, also known as Al, Ph D., has been an Independent Director at BioNano Genomics, Inc. since October 2011 and is its Chairman since June 18, 2024 and serves as Interim President, Interi...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | no data | US$95.72k | Nessun dato | |
| Chief Operating Officer | 8.5yrs | US$756.33k | 0.0058% $ 800.5 | |
| Chief Medical Officer | 5.8yrs | US$756.33k | 0.0058% $ 799.1 | |
| VP of Accounting | 7.9yrs | Nessun dato | 0.0023% $ 321.8 | |
| General Counsel & Secretary | 4.2yrs | Nessun dato | 0.0024% $ 326.0 | |
| Global Head of People Operations | 4.3yrs | Nessun dato | Nessun dato |
5.0yrs
Durata media
51yo
Età media
Gestione esperta: Il team dirigenziale di BNGO è esperto e expertise (durata media dell'incarico 5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 14.6yrs | US$95.72k | Nessun dato | |
| Lead Independent Director | 7.8yrs | US$68.43k | 0.00096% $ 132.0 | |
| Independent Director | 16yrs | US$73.43k | 0.00087% $ 119.7 | |
| Independent Director | 7yrs | US$66.70k | 0% $ 0 | |
| Independent Director | 6yrs | US$54.96k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$53.43k | 0% $ 0 |
7.4yrs
Durata media
64yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BNGO sono considerati esperti (durata media dell'incarico 7.4 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 13:49 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Bionano Genomics, Inc. è coperta da 5 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |